This HTML5 document contains 92 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n25http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00290/identifier/chemspider/
n22http://linked.opendata.cz/resource/AHFS/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00290/identifier/chebi/
foafhttp://xmlns.com/foaf/0.1/
n28http://linked.opendata.cz/resource/mesh/concept/
n5http://linked.opendata.cz/resource/drugbank/company/
n23http://linked.opendata.cz/resource/drugbank/dosage/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00290/identifier/wikipedia/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00290/identifier/pharmgkb/
n9http://bio2rdf.org/drugbank:
n14http://linked.opendata.cz/resource/drugbank/drug/DB00290/identifier/kegg-compound/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00290/identifier/bindingdb/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00290/identifier/pdb/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00290/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n31http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00290/identifier/pubchem-substance/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00290/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n30http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n27http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n20http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00290/identifier/national-drug-code-directory/
xsdhhttp://www.w3.org/2001/XMLSchema#
n24http://linked.opendata.cz/resource/atc/
n21http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00290
rdf:type
n3:Drug
n3:description
A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.
n3:dosage
n23:271B4B6C-363D-11E5-9242-09173F13E4C5 n23:271B4B6D-363D-11E5-9242-09173F13E4C5 n23:271B4B6E-363D-11E5-9242-09173F13E4C5 n23:271B4B6B-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Claussen CA, Long EC: Nucleic Acid recognition by metal complexes of bleomycin. Chem Rev. 1999 Sep 8;99(9):2797-816. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11749501
n3:group
approved
n3:halfLife
115 minutes
n3:indication
For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.
n3:manufacturer
n5:271B4B66-363D-11E5-9242-09173F13E4C5 n5:271B4B64-363D-11E5-9242-09173F13E4C5 n5:271B4B65-363D-11E5-9242-09173F13E4C5 n5:271B4B62-363D-11E5-9242-09173F13E4C5 n5:271B4B63-363D-11E5-9242-09173F13E4C5 n5:271B4B61-363D-11E5-9242-09173F13E4C5
owl:sameAs
n9:DB00290 n31:DB00290
dcterms:title
Bleomycin
adms:identifier
n7:46509116 n10:PA448645 n11:5360373 n12:0703-3154-01 n13:BLM n14:C06854 n15:4514492 n16:DB00290 n17:50122169 n18:22907 n26:Bleomycin
n3:mechanismOfAction
Although the exact mechanism of action of bleomycin is unknown, available evidence would seem to indicate that the main mode of action is the inhibition of DNA synthesis with some evidence of lesser inhibition of RNA and protein synthesis. DNA cleavage by bleomycin depends on oxygen and metal ions, at least in vitro. It is believed that bleomycin chelates metal ions (primarily iron) producing a pseudoenzyme that reacts with oxygen to produce superoxide and hydroxide free radicals that cleave DNA.
n3:packager
n5:271B4B5E-363D-11E5-9242-09173F13E4C5 n5:271B4B5F-363D-11E5-9242-09173F13E4C5 n5:271B4B5C-363D-11E5-9242-09173F13E4C5 n5:271B4B5D-363D-11E5-9242-09173F13E4C5 n5:271B4B60-363D-11E5-9242-09173F13E4C5 n5:271B4B5A-363D-11E5-9242-09173F13E4C5 n5:271B4B5B-363D-11E5-9242-09173F13E4C5 n5:271B4B59-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
It was reported that patients with moderately severe renal failure excreted less than 20% of the dose in the urine.
n3:synonym
Bleomycinum Bleocin Bleomycin A2 Bleomicina Bleomicin BLM Bleomycine
n3:toxicity
Excessive exposure may cause fever, chills, nausea, vomiting, mental, confusion, and wheezing. Bleomycin may cause irritation to eyes, skin and respiratory tract. It may also cause a darkening or thickening of the skin. It may cause an allergic reaction.
n21:hasAHFSCode
n22:10-00-00
n3:proteinBinding
1%
n3:salt
n3:synthesisReference
Hamao Umezawa, Kenji Maeda, Tomohisa Takita, Yuya Nakayama, Akio Fujii, Nobuyoshi Shimada, Hideo Chimura, "Novel process for producing antibiotics bleomycin." U.S. Patent USRE0304514, issued October, 1970.
n27:hasConcept
n28:M0002657
foaf:page
n20:bleomycin.html n25:bleomycin.htm
n3:IUPAC-Name
n4:271B4B73-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4B79-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4B78-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4B75-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4B76-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4B77-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4B71-363D-11E5-9242-09173F13E4C5 n4:271B4B89-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4B6F-363D-11E5-9242-09173F13E4C5 n4:271B4B72-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4B70-363D-11E5-9242-09173F13E4C5
n21:hasATCCode
n24:L01DC01
n3:H-Bond-Acceptor-Count
n4:271B4B7F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4B80-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4B7A-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4B7B-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4B7D-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4B7C-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4B7E-363D-11E5-9242-09173F13E4C5
n3:absorption
Systemic absorption is approximately 45%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
11056-06-7
n3:category
n3:containedIn
n30:271B4B68-363D-11E5-9242-09173F13E4C5 n30:271B4B69-363D-11E5-9242-09173F13E4C5 n30:271B4B67-363D-11E5-9242-09173F13E4C5 n30:271B4B6A-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4B85-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4B87-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4B88-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4B8A-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4B84-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4B83-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4B86-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4B74-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4B81-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4B82-363D-11E5-9242-09173F13E4C5